Further study of EGFR-based therapy in patients’ subgroups, either selected by clinical parameters (e.g., with locally advanced disease) or defined by molecular subtype (e.g., KRAS wild-type pancreatic cancer) may be warranted, and an increased understanding of primary resistance, role of intracellular redundancy and cross-talk amongst signalling pathways, acquired resistance, interaction of EGFR inhibitors with chemotherapy and potential biomarkers of their activity are necessary for successful trial design in this disease group. Here, EGFR is linked to familial pancreatic carcinoma.